Visser, PJ, Reus, LM, Gobom, J, Jansen, I, Dicks, E, Van der Lee, SJ, Tsolaki, M, Verhey, FRJ, Popp, J, Martinez-Lage, P, Vandenberghe, R, Lleo, A, Molinuevo, JL, Engelborghs, S, Freund-Levi, Y, Froelich, L, Sleegers, K, Dobricic, V, Lovestone, S, Streffer, J, Vos, SJB, Bos, I, Smit, AB, Blennow, K, Scheltens, P, Teunissen, CE, Bertram, L, Zetterberg, H, Tijms, BM. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration. 2022; 17(1)DOI:10.1186/s13024-022-00521-3. PMID:35346299. IF:15.100(Q1/1D).

Homann, J, Osburg, T, Ohlei, O, Dobricic, V, Deecke, L, Bos, I, Vandenberghe, R, Gabel, S, Scheltens, P, Teunissen, CE, Engelborghs, S, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Lleo, A, Alcolea, D, Popp, J, Clark, C, Peyratout, G, Martinez-Lage, P, Tainta, M, Dobson, RJB, Legido-Quigley, C, Sleegers, K, Van Broeckhoven, C, Wittig, M, Franke, A, Lill, CM, Blennow, K, Zetterberg, H, Lovestone, S, Streffer, J, ten Kate, M, Vos, SJB, Barkhof, F, Visser, PJ, Bertram, L. Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience. 2022; 14DOI:10.3389/fnagi.2022.840651. PMID:35386118. IF:4.800(Q2/3D).

Garcia-Sanchez, C, Calabria, M, Grunden, N, Pons, C, Arroyo, JA, Gomez-Anson, B, Lleo, A, Alcolea, D, Belvis, R, Morollon, N, Mur, I, Pomar, V, Domingo, P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3)DOI:10.1002/brb3.2508. PMID:35137561. IF:3.100(Q2/3D).

Illan-Gala, I, Montal, V, Borrego-Ecija, S, Mandelli, ML, Falgas, N, Welch, AE, Pegueroles, J, Santos-Santos, M, Bejanin, A, Alcolea, D, Dols-Icardo, O, Belbin, O, Sanchez-Saudinos, MB, Bargallo, N, Gonzalez-Ortiz, S, Llado, A, Blesa, R, Dickerson, BC, Rosen, HJ, Miller, BL, Lleo, A, Gorno-Tempini, ML, Sanchez-Valle, R, Fortea, J. Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimers Research & Therapy. 2022; 14(1)DOI:10.1186/s13195-022-00974-0. PMID:35139897. IF:9.000(Q1/1D).

Gonzalez, AC, Belbin, O. Fluid markers of synapse degeneration in synucleinopathies. JOURNAL OF NEURAL TRANSMISSION. 2022; 129(2)DOI:10.1007/s00702-022-02467-8. PMID:35147800. IF:3.300(Q2/5D).

Delaby, C, Alcolea, D, Hirtz, C, Vialaret, J, Kindermans, J, Morichon, L, Fortea, J, Belbin, O, Gabelle, A, Blennow, K, Zetterberg, H, Lleo, A, Lehmann, S. Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. JOURNAL OF NEURAL TRANSMISSION. 2022; 129(2)DOI:10.1007/s00702-022-02474-9. PMID:35169889. IF:3.300(Q2/5D).

Delaby, C, Estelles, T, Zhu, NU, Arranz, J, Barroeta, I, Carmona-Iragui, M, Illan-Gala, I, Santos-Santos, MA, Altuna, M, Sala, I, Sanchez-Saudinos, MB, Videla, L, Valldeneu, S, Subirana, A, Tondo, M, Blanco-Vaca, F, Lehmann, S, Belbin, O, Blesa, R, Fortea, J, Lleo, A, Alcolea, D. The A beta 1-42/A beta 1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A beta 1-42 alone. Alzheimers Research & Therapy. 2022; 14(1)DOI:10.1186/s13195-022-00967-z. PMID:35105351. IF:9.000(Q1/1D).

Delaby, C, Lehmann, S. Proteinopathies: molecular mechanisms and diagnostic perspectives (vol 129, pg 129, 2022). JOURNAL OF NEURAL TRANSMISSION. 2022; 129(2)DOI:10.1007/s00702-022-02473-w. PMID:35175386. IF:3.300(Q2/5D).